FibroBiologics Reports Preclinical Data Supporting CYPS317 for Psoriasis Treatment

FibroBiologics (NASDAQ:FBLG) presented preclinical data on its fibroblast spheroid therapy, CYPS317, at the Society for Investigative Dermatology Annual Meeting. The results showed reduced psoriasis severity in mouse models with improved safety and sustained therapeutic activity compared to single-cell approaches.

By Laiba Immad Tue, June 2, 2026 at 4:57 PM GMT+3 2 min read · Yahoo Finance · June 2, 2026, 13:57 UTC

Topics: fibroblast therapy Hantavirus pulmonary syndrome preclinical data psoriasis

Read the full article at Yahoo Finance

More World news

SpaceX Partners with Qualcomm to Launch Starlink Mobile Cellular Service Motley Fool · November 12, 2026, 15:21 UTC
Blast Resources Appoints Andy Yackulic as CEO to Lead Uranium Exploration PR Newswire · November 12, 2026, 15:26 UTC
FMC Corporation Shares Decline 13% in Thursday Trading Seeking Alpha · November 12, 2026, 15:22 UTC
U.S. Stock Indices Decline Following Nvidia CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 15:23 UTC
EY Report Outlines Three Fundamental Shifts Required for Future-Ready Health Systems by 2040 PR Newswire · November 12, 2026, 15:24 UTC
ProLift Garage Doors Expands Franchise Services and Support Initiatives PR Newswire · November 12, 2026, 15:24 UTC
Pomerantz Law Firm Investigates Cerebras Systems Inc. Over Potential Securities Fraud PR Newswire · November 12, 2026, 15:25 UTC
CEZ Reports 9M Revenue Growth and 24% Increase in Net Income Seeking Alpha · November 12, 2026, 15:05 UTC
BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC